Last reviewed · How we verify
Standard hyponatremia treatment
Standard hyponatremia treatment is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Hyponatremia (symptomatic or severe).
Standard hyponatremia treatment typically involves fluid restriction and/or sodium supplementation to restore normal serum sodium levels.
Standard hyponatremia treatment typically involves fluid restriction and/or sodium supplementation to restore normal serum sodium levels. Used for Hyponatremia (symptomatic or severe).
At a glance
| Generic name | Standard hyponatremia treatment |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Nephrology |
| Phase | Phase 3 |
Mechanism of action
Hyponatremia (low blood sodium) is managed through multiple approaches depending on acuity and cause: acute symptomatic hyponatremia may require hypertonic saline infusion to rapidly raise sodium levels, while chronic hyponatremia is often managed with fluid restriction to allow gradual sodium normalization. The underlying mechanism depends on the specific treatment modality employed, ranging from osmotic correction via saline administration to water balance restoration through fluid intake limitation.
Approved indications
- Hyponatremia (symptomatic or severe)
Common side effects
- Osmotic demyelination syndrome (with overly rapid correction)
- Hypernatremia (overcorrection)
- Fluid overload (with hypotonic solutions)
Key clinical trials
- Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure. (NA)
- Validation of New Diagnostic Indices to Simplify Hyponatremia Therapy Assessment in Patients on Thiazide Diuretics (NA)
- CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS (PHASE4)
- Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma (PHASE1)
- Evaluation of Volume and Electrolyte Balance in Hyponatremia Treatment - a Prospective Observational Trial
- Targeted Correction of Plasma Sodium Levels in Hospitalized Patients With Hyponatremia (NA)
- Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia (PHASE3)
- A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard hyponatremia treatment CI brief — competitive landscape report
- Standard hyponatremia treatment updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Standard hyponatremia treatment
What is Standard hyponatremia treatment?
How does Standard hyponatremia treatment work?
What is Standard hyponatremia treatment used for?
Who makes Standard hyponatremia treatment?
What development phase is Standard hyponatremia treatment in?
What are the side effects of Standard hyponatremia treatment?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Endocrinology / Nephrology
- Indication: Drugs for Hyponatremia (symptomatic or severe)
- Compare: Standard hyponatremia treatment vs similar drugs
- Pricing: Standard hyponatremia treatment cost, discount & access